Grantham, Mayo, Van Otterloo & Co (GMO)
NVAX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Novavax NVAX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,700
Closed -$345K – 768
2022
Q2 		$345K Buy
+6,700
New +$347K ﹤0.01% 656

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s NVAX Position: Q3 2022 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Novavax (NVAX) in Q3 2022, closing a stake of 6,700 shares — an estimated $345K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NVAX in Q2 2022 and held it in 1 quarter. The position peaked at $345K in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 6,700 Novavax shares in Q3 2022, an estimated $345K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Novavax in Q2 2022 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Novavax position peaked at $345K in Q2 2022.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2022, filed 10 Nov 2022.